What Alkermes stock’s recent move might mean for investors
Alkermes (ALKS) has drawn fresh attention after its shares moved around recent trading, with a last close of $34.84 and positive returns over the week, month, and past 3 months.
See our latest analysis for Alkermes.
The recent 7 day share price return of 16.44% and 30 day return of 19.32% sit alongside a 5 year total shareholder return of 85.87%. Together, these figures indicate that momentum has been present over both shorter and longer horizons.
If Alkermes has caught your eye, it may be worth widening the lens to other healthcare names using our screener of 37 healthcare AI stocks
With Alkermes trading at $34.84, a value score of 4, and an implied gap to an analyst price target of $43.71, is the stock still attractively priced for new capital, or have markets already incorporated expectations for future growth?
Most Popular Narrative: 20.3% Undervalued
Alkermes last closed at $34.84 compared with a narrative fair value of $43.71, which frames the current debate around how durable its growth story really is.
The company is benefitting from margin expansion efforts and cost discipline, seen in lower cost of goods sold post divestiture of lower margin manufacturing operations, which, together with growing proprietary product sales, is driving higher net margins and increasing free cash flow generation. Alkermes' strong cash position, lack of debt, and opportunistic share repurchase authorization provide financial flexibility to accelerate pipeline programs, pursue external growth options, and support sustained earnings growth while minimizing dilution risk to shareholders.
Curious how this mix of cost discipline, neuroscience products, and a sleep pipeline adds up to that fair value? The key assumptions around revenue, earnings, and future P/E multiples might surprise you.
Result: Fair Value of $43.71 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on the newer sleep franchise delivering as expected, while rising R&D spend and product concentration around a few key drugs could challenge that story.
Find out about the key risks to this Alkermes narrative.
Next Steps
The mix of optimism and concern around Alkermes is clear, and the balance of risks and rewards is finely poised. Review the detail for yourself and see the full picture with 3 key rewards and 1 important warning sign
Ready to hunt for your next idea?
If you stop with just one stock, you could miss opportunities that fit your style even better. Put a few minutes into comparing ideas and give yourself options.
- Target stability and income by scanning for companies that combine higher yields with resilient profiles using the 12 dividend fortresses.
- Spot potential value candidates by filtering for quality companies that the market may have priced cautiously with the 62 high quality undervalued stocks.
- Prioritise resilience by focusing on companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (39 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com